| Cancer statistics, 2019 | Ca-A Cancer Journal for Clinicians | 2019 | 12.7K |
| Cancer treatment and survivorship statistics, 2019 | Ca-A Cancer Journal for Clinicians | 2019 | 1.9K |
| Breast cancer statistics, 2019 | Ca-A Cancer Journal for Clinicians | 2019 | 1.1K |
| ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells | Biology of Blood and Marrow Transplantation | 2019 | 874 |
| Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia | Blood | 2019 | 811 |
| Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic | Annals of Oncology | 2019 | 784 |
| Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† | Annals of Oncology | 2019 | 528 |
| Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue | Journal of Clinical Apheresis | 2019 | 450 |
| The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas | Blood | 2019 | 431 |
| Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications | Journal of Hematology and Oncology | 2019 | 375 |
| Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† | Annals of Oncology | 2019 | 372 |
| Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry | Annals of Oncology | 2019 | 365 |
| CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) | Annals of Oncology | 2019 | 363 |
| Ferroptosis, a new form of cell death: opportunities and challenges in cancer | Journal of Hematology and Oncology | 2019 | 330 |
| Cancer statistics for African Americans, 2019 | Ca-A Cancer Journal for Clinicians | 2019 | 330 |
| Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 | Annals of Oncology | 2019 | 325 |
| Targeting FLT3 mutations in AML: review of current knowledge and evidence | Leukemia | 2019 | 324 |
| Artificial intelligence in cancer imaging: Clinical challenges and applications | Ca-A Cancer Journal for Clinicians | 2019 | 319 |
| Recommendations for the management of hemophagocytic lymphohistiocytosis in adults | Blood | 2019 | 318 |
| Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study | Annals of Oncology | 2019 | 313 |
| Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management | Blood Reviews | 2019 | 313 |
| Anemia of inflammation | Blood | 2019 | 303 |
| American Society of Hematology 2019 guidelines for immune thrombocytopenia | Blood Advances | 2019 | 299 |
| ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease† | Annals of Oncology | 2019 | 298 |
| Epithelial ovarian cancer: Evolution of management in the era of precision medicine | Ca-A Cancer Journal for Clinicians | 2019 | 292 |
